A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate

Jason N Barreto; Kianoush B Kashani; Kristin C Mara; Andrew D Rule; John C Lieske; Callen D Giesen; Carrie A Thompson; Nelson Leung; Thomas E Witzig; Erin F Barreto

doi:10.1016/j.ekir.2022.03.013

A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate

Kidney Int Rep. 2022 Mar 26;7(7):1690-1693. doi: 10.1016/j.ekir.2022.03.013. eCollection 2022 Jul.

Authors

Affiliations

¹ Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
² Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
³ Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
⁵ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁶ Department of Pharmacy, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA.

No abstract available

Keywords: TIMP2∗IGFBP7; insulin-like growth factor binding protein-7; methotrexate; nephrotoxicity; neutrophil gelatinase-associated lipocalin (NGAL); tissue inhibitor metalloproteinase-2.

Grants and funding

K23 AI143882/AI/NIAID NIH HHS/United States